Medically reviewed by Abhijit Bhattacharyya | MD, PhD, MBA, Tufts University School of Medicine - Miami, Florida on November 17th, 2025.
Important Note: Orforglipron is not yet FDA-approved. This medication is currently in clinical trials, with Eli Lilly planning to submit for regulatory review in late 2025, with potential FDA approval expected in 2026.
The weight loss medication landscape is evolving rapidly, and one of the most anticipated developments is orforglipron—the first oral GLP-1 receptor agonist designed specifically for weight management. Unlike current GLP-1 medications that require weekly injections, this daily pill could transform how millions of people approach weight loss treatment.
Orforglipron is an investigational once-daily oral medication that mimics the effects of GLP-1 (glucagon-like peptide-1), a naturally occurring hormone that regulates appetite and blood sugar. What makes orforglipron unique is its chemical structure — it's a "small molecule" non-peptide drug, which allows it to survive digestion and be taken as a pill, unlike injectable GLP-1s which are peptides that would be destroyed by stomach acids.
Clinical trials have demonstrated promising results. In this study of 3,127 adults with obesity or overweight, participants taking the highest dose (36 mg) lost an average of 12.4% of their body weight (27.3 pounds) over 72 weeks, compared to just 2.1% (2.2 pounds) with placebo.
Additionally, 59.6% of participants taking the highest dose lost at least 10% of their body weight, while 39.6% lost at least 15%—results comparable to many injectable GLP-1 medications.
Orforglipron works by activating GLP-1 receptors in the body, which helps control appetite, slow gastric emptying, and improve how the body processes glucose. The medication can be taken any time of day without food or water restrictions, offering significant flexibility compared to other oral medications.
In clinical trials, the most common side effects included:
Nausea
Diarrhea
Vomiting
In most cases these side effects were mild to moderate in severity. Orforglipron’s safety profile observed in clinical trials has been consistent with other GLP-1 receptor agonists. Treatment discontinuation rates ranged from 21.9% to 24.4% across dosages, compared to 29.9% with placebo.
While orforglipron's official pricing has not been announced, there are reasons to be hopeful about affordability. In November 2025, Eli Lilly and the U.S. government reached an agreement that would provide Medicare beneficiaries with access to orforglipron (if approved) at $50 per month.
For context, current injectable GLP-1 medications like Wegovy and Zepbound typically cost $1,000-$1,400 per month without insurance coverage. The potential for significantly lower pricing with orforglipron reflects several factors:
Manufacturing advantages: As a small molecule drug, orforglipron may be less expensive to produce than biological peptide medications
No cold storage requirement: Eliminating refrigeration needs could reduce distribution costs
Government partnerships: The Medicare pricing agreement suggests efforts to ensure broad accessibility
It's important to note that actual out-of-pocket costs will depend on insurance coverage, which won't be determined until after FDA approval. Many insurance plans have varying coverage policies for weight loss medications, and some don't cover them at all.
If regulatory submissions proceed as planned and FDA approval is granted, orforglipron could become available sometime in 2026. However, these timelines depend on completion of ongoing trials and the regulatory review process.
While orforglipron represents an exciting future option for weight management, it's important to remember that it's not yet available. If you're interested in medically-supervised weight loss treatment now, Doctronic can help you access FDA-approved weight loss medications, including currently available GLP-1 options. Our platform connects you with licensed healthcare providers who can evaluate your needs and prescribe appropriate, evidence-based treatments that are available today.
Important Note: Orforglipron is not yet FDA-approved. This medication is currently in clinical trials, with Eli Lilly planning to submit for regulatory review in late 2025, [...]
Read More
